ANI-7

• Product Name Alternative:

  Prodigiosine (hydrochloride)

• UNSPSC Description:

  ANI-7 is an activator of aryl hydrocarbon receptor (AhR) pathway. ANI-7 inhibits the growth of multiple cancer cells, and potently and selectively inhibits the growth of MCF-7 breast cancer cells with a GI50 of 0.56 μM. ANI-7 induces CYP1-metabolizing mono-oxygenases by activating AhR pathway, and also induces DNA damage, checkpoint Kinase 2 (Chk2) activation, S-phase cell cycle arrest, and cell death in sensitive breast cancer cell lines[1][2][3].

• Target Antigen:

  Aryl Hydrocarbon Receptor; Checkpoint Kinase (Chk)

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Immunology/Inflammation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ani-7.html

• Purity:

  98.13

• Solubility:

  DMSO : 20.83 mg/mL (ultrasonic)

• Smiles:

  ClC1=CC(/C(C#N)=C/C2=CC=CN2)=CC=C1Cl

• Molecular Weight:

  263.12

• References & Citations:

  [1]ilbert J, et al. (Z)-2-(3,4-Dichlorophenyl)-3-(1H-Pyrrol-2-yl)Acrylonitrile Exhibits Selective Antitumor Activity in Breast Cancer Cell Lines via the Aryl Hydrocarbon Receptor Pathway. Mol Pharmacol. 2018 Feb;93(2):168-177.|[2]Baker JR, et al. Dichlorophenylacrylonitriles as AhR Ligands That Display Selective Breast Cancer Cytotoxicity in vitro. ChemMedChem. 2018 Jul 18;13(14):1447-1458.|[3]Mark Tarleton, et al. Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound.  Medicinal Chemistry Communication. January 20112. (1):31-37.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  931417-26-4